The conversion of RAS status in metastatic colorectal cancer patients after first-line biological agent treatment.

Serdar ArıcıJamshid HamdardAbdullah SakinSelma Sengiz ErhanMuhammed Mustafa AtciRuhper CekinBurcu SakaEmin KöseTuba SaydamCaglayan GeredeliSener CihanAhmet Bilici

Published in: Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland (2020)

Our results suggest that re-biopsy is needed for an optimal second-line treatment decision in mCRC patients regardless of backbone biological agent, especially in patients with wild-type RAS mCRC.

Keyphrases

end stage renal disease
wild type
newly diagnosed
ejection fraction
chronic kidney disease
peritoneal dialysis
metastatic colorectal cancer
fine needle aspiration